Pharmaceuticals, Biotechnology and Life Sciences
Pfizer said on Thursday it would sell its global infusion therapy business, part of its $15 billion (11.8 billion pounds) Hospira acquisition last year, to ICU Medical Inc for $1 billion in cash and stock.
AstraZeneca’s heart drug Brilinta has failed to help patients with serious circulatory problems in their legs, dealing a blow to a medicine that the company has tipped as a potential $3.5 billion-a-year seller by 2023.
Pfizer, which was considering splitting itself for more than two years, said on Monday it would not do so, prompting shareholders to expect more deals that could bolster its roster of new medicines.
Horizon Pharma and Raptor Pharmaceutical Corp.have entered into a definitive agreement under which Horizon Pharma will acquire all of the issued…
Verona Pharma #VRP appoints Vikas Sinha to the Board as a Non-Executive Director
The study, which will be conducted in up to 70 healthy individuals, aims to evaluate the tolerability of KarXT compared to xanomeline alone.
Dechra, an international specialist veterinary pharmaceuticals company, has received approval from the U.S. Food and Drug Administration (FDA) for a generic antibiotic.
Redx CFO steps down, the company searches new one
David Evans, Non-executive Chairman, has stepped down from the Board with immediate effect.
Quay Pharma will be formulating the capsules that will be administered in Redx’s trial.